HOME >> BIOLOGY >> NEWS
APP reports Abraxane(TM) is active in breast cancer patients who failed taxol or taxotere

NEW ORLEANS, LA; SCHAUMBURG, IL June 7, 2004 Abraxis Oncology, a division of American Pharmaceutical Partners, Inc. (APP) (NASDAQ: APPX) today said that results from a 106 patient Phase II study of ABRAXANE in patients with advanced breast cancer whose disease had progressed while they were being treated with TAXOL and Taxotere responded to subsequent treatment with ABRAXANETM (albumin nanoparticle paclitaxel). The results were presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in New Orleans, LA, by Joanne Blum, M.D., Ph.D., of the Charles A. Sammons Cancer Center, Baylor University Medical Center in Dallas, TX, one of 38 US Oncology affiliated practices that had patients participate in this clinical study of ABRAXANE.

The Phase II study, sponsored by American BioScience, included 106 patients with progressive metastatic breast cancer whose disease had progressed while being treated with TAXOL or Taxotere in the metastatic setting, or had a relapse within 12 months of adjuvant taxane therapy. The patients enrolled in this study had a very poor prognosis, with 91% having visceral (lung and liver) disease, 65% with more than three metastatic sites, and 88% demonstrating ongoing tumor growth while receiving TAXOL and/or Taxotere in the metastatic setting. Evidence of the activity of weekly doses of ABRAXANE in this highly refractory population is provided by the following findings:

  • A 15% overall response rate (95% CI: 8%-22%) in the 106 patients studied with a 38% probability of survival at 12 months based on analysis of data to date;
  • 40% of patients on treatment with ABRAXANETM were free of disease progression for as long as four months; and almost 30% for as long as six months;
  • Of those patients who progressed while on Taxotere alone in the metastatic setting (n=33), a 24% response rate was noted after receiving weekly ABRAXANETM;
  • Of those patients who pr
    '"/>


Contact: Melyssa Weible
MWeible@healthstarpr.com
646-328-1457
HealthStar PR
7-Jun-2004


Page: 1 2 3 4

Related biology news :

1. Scientists question reports of massive ant supercolonies in California and Europe
2. Survey reports fall in stem cell transplants for breast cancer
3. VaxGen reports Phase I clinical trial results of anthrax vaccine candidate
4. Immerge reports PERVs most infectious to human cells not part of germ-line DNA of mini-swine
5. By the year 2050, human population could add 2.6 billion people, reports Rockefeller scientist
6. Measles on the rise as vaccinations fall in the UK, Science study reports
7. WCS biologist George Schaller reports surprising increase in Tibets wildlife
8. Clinical study reports findings of combination therapy with DOXIL
9. Europes population has developed new tendency to shrink, Science study reports
10. U of A scientist finds Atlantic salmon escapes higher than government reports
11. Cyclis Pharmaceuticals reports studies defining new mechanism for potential cancer therapies

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/16/2019)... (PRWEB) , ... April 16, 2019 , ... ... markets, celebrated the grand opening of its new medical device facility on Friday, ... , Located in Memphis, TN the new facility includes 108,500 square feet and ...
(Date:4/12/2019)... (PRWEB) , ... April 11, 2019 , ... ... is excited to announce their efforts to help decrease opioid abuse by offering ... no charge or a discounted rate, up to 50% off. , In 2019, ...
(Date:4/4/2019)... , ... April 02, 2019 , ... ... and development solutions for drugs, biologics and consumer health products, today announced that ... takes place at the Gaylord National Harbor Hotel, Oxon Hill, Maryland, on April ...
Breaking Biology News(10 mins):
(Date:4/8/2019)... ... April 08, 2019 , ... CallTower, ... today the launch of their app integration solution, CT Cloud Unite. CT ... applications while using CT Cloud Voice and Skype for Business solutions. This robust ...
(Date:3/29/2019)... ... March 28, 2019 , ... Specific Diagnostics announced ... proceeded with a second stage of funding for Specific’s Reveal™ rapid antibiotic susceptibility ... top of the $1.7 million already awarded by CARB-X. The additional $1.7M will ...
(Date:3/23/2019)... Pa. (PRWEB) , ... March 22, 2019 , ... ... of its LenS3 Multi-Angle Light Scattering (MALS) detector , offering a revolutionary ... of synthetic polymers, polysaccharides, proteins, and biopolymers. A novel optical design, a unique ...
(Date:3/19/2019)... ... ... webinar will review strategies for data management in modular and adaptive clinical trials. , ... up to 30 percent, reducing cost while increasing quality, achieving clinical site set-up faster , ... data – reducing risk and impact on trial success, trial teams, and trial execution , ...
Breaking Biology Technology:
Cached News: